Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial
Rigby, Mark R, DiMeglio, Linda A, Rendell, Marc S, Felner, Eric I, Dostou, Jean M, Gitelman, Stephen E, Patel, Chetanbabu M, Griffin, Kurt J, Tsalikian, Eva, Gottlieb, Peter A, Greenbaum, Carla J, SheТом:
1
Мова:
english
Журнал:
The Lancet Diabetes & Endocrinology
DOI:
10.1016/S2213-8587(13)70111-6
Date:
December, 2013
Файл:
PDF, 569 KB
english, 2013
File converter
Більше результатів пошуку
More benefits 
